



PRESS RELEASE

IMMUNOBIOLOGY (IMMBIO) EXTEND ITS COLLABORATION WITH EDEN BIODESIGN TO DEVELOP A NEW GENERATION VACCINE FOR INFLUENZA

Liverpool/Cambridge, UK; 12 November 2007: Eden Biodesign Ltd, an expert provider of development and cGMP manufacturing services for biological therapies and ImmBio (Cambridge, UK), a leading biotechnology company developing the next generation of anti-infective vaccines, have elected to extend their initial collaboration to develop ImmBio's innovative influenza vaccine. The new contract covers a range of development and cGMP manufacturing services to produce material for ImmBio's Phase I clinical trial.

Influenza viral mutation and reassortment leads to frequent strain drift, while a major strain shift could result in a pandemic. Consequently the key need for a next generation vaccine product and associated manufacturing process is flexibility and speed. ImmBio's approach is to use ImmunoBodies™ technology which couples the Fc region of an antibody to influenza haemagglutinin (HA).

Each strain of influenza is characterized using the antigenic structure of HA , with 15 known subtypes. Studies conducted have successfully demonstrated that ImmunoBodies™ can be produced for the different subtypes, including high-pandemic risk H5 and current seasonal H3.

Graham Clarke, CEO of ImmBio said: "We are pleased to extend our on-going relationship with Eden Biodesign and to work closely with the company to ensure effective and timely development of our leading product. We intend to progress along aggressive timelines towards clinical testing of our innovative vaccine which has the potential to revolutionise the flu vaccination market."

Dr Crawford Brown, CEO of Eden Biodesign commented: "We are delighted that ImmBio decided to extend their collaboration with us. It is our aim to develop long term relationships with our clients by ensuring that we conduct our business in an open and honest way, having the ultimate success of our clients' products in mind".

Ends

For further information contact:



Sylvie Berrebi, De Facto Communications Ltd +44 (0)20 7861 3838
Email S.Berrebi@Defacto.com

Graham Clarke, ImmunoBiology Ltd +44 (0)1223 496117
Email graham.clarke@immunobiology.co.uk

Notes to editors:

Eden Biodesign

Eden Biodesign is a successful international biopharmaceutical development and manufacturing services business that provides 'state of the art' development and manufacturing services to biotech clients across Europe, the USA and Asia. It promises all clients a committed service plus the knowledge and expertise to guide clients through process development, manufacturing, regulatory and technology transfer challenges.

The company uses the principles of 'Good Science' at every step of biopharmaceutical development to design programmes and processes that deliver clinically and commercially valuable products, with an accomplished and attentive level of project management that clients need. For further information please visit www.edenbiodesign.com.

ImmBio

ImmBio is a vaccine company developing the next generation of anti-infective vaccines, addressing areas of high unmet need, where the risk and consequence of infection are severe.

It is progressing a development portfolio of break-through products utilizing its HspC™ platform technology and ImmunoBodies™ technology. TB, supported by the Aeras Global TB Vaccine Foundation, in turn funded by the Bill & Melinda Gates Foundation is the lead bacterial product. Influenza, protective against both seasonal and pandemic strains, is the lead viral product. ImmBio is based at the Babraham Research Campus in Cambridge UK. For further information please visit www.immbio.com

The National Biomanufacturing Centre

The £34.25 million National Biomanufacturing Centre which was officially opened in November 2006, is a Government-funded initiative led by the Northwest Regional Development Agency (NWDA) additionally funded through the European Regional Development Fund (ERDF) and the Department of Trade and Industry (DTI) and aims to establish England's Northwest as one of the foremost biomanufacturing centres in Europe.



The centre provides the expertise and facilities to support new and existing biotechnology companies, offering product development services designed to fill in the skill and resource gaps that exist within these organisations. It also provides training in biomanufacturing and analytical sciences, delivering the skilled workforce required to expand the UK biopharmaceutical sector.

There is also an Access Fund of nearly £3 million funded by the Department of Trade and Industry and the European Regional Development Fund, which is available to qualifying small-to-medium companies and academic groups in the biotechnology sector to assist them in purchasing development and clinical manufacturing services from the Centre. www.biomanufacturing.co.uk